HIV Envelope Protein Mutation Detection for Entry Inhibitor Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting resistance to HIV entry inhibitors are inadequate for rapid and efficient identification, particularly in clinical settings, as they lack sensitivity and specificity in assessing changes in viral susceptibility over time.
Innovation Solution
A method involving comparison of envelope protein variable regions and glycosylation sites between HIV and reference strains, including detection of specific mutations in codons, to determine resistance to entry inhibitors such as PRO542, TNX-355, and monoclonal antibodies, using phenotypic and genotypic assays to guide therapeutic decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for detecting resistance to HIV entry inhibitors, then detection can be performed, but the sensitivity and specificity are insufficient and the process is not rapid enough for clinical settings
Solution Approach 1:
The patent replaces complex phenotypic resistance testing (mechanical/biological system) with genotypic analysis of envelope protein sequences (molecular system). By identifying specific mutations in the env gene that correlate with resistance, the method achieves rapid detection without requiring time-consuming viral culture and susceptibility testing, thereby improving both precision and speed for clinical application
Solution Approach 2:
The invention changes the detection parameter from measuring viral susceptibility phenotypes to analyzing genetic sequence characteristics. By focusing on specific mutations in envelope protein variable regions and glycosylation sites, the method transforms a complex biological measurement into a targeted molecular analysis, enabling faster and more precise resistance detection
2Measurement precision
If comprehensive phenotypic assays are performed to accurately assess viral susceptibility, then measurement precision improves, but the complexity and time required for testing increases
Solution Approach 1:
The patent extracts the essential resistance-determining information from the complex envelope protein by focusing on specific critical regions (variable regions V1-V5 and glycosylation sites). Instead of analyzing the entire protein or performing comprehensive phenotypic assays, the method isolates and analyzes only the mutations in key codons that are most strongly associated with resistance, thereby simplifying the assay while maintaining accuracy
Solution Approach 2:
The invention segments the envelope protein analysis into discrete, testable genetic markers. By dividing the env gene into specific variable regions and identifying particular mutations in each, the method creates a modular approach to resistance testing that is both comprehensive and manageable, reducing overall assay complexity while preserving measurement precision
Data Source
AI summary
The invention provides a method for treating a patient having human immunodeficiency virus (HIV) infection by determining whether the human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV and treating the patient based on that determination. In certain aspects, the methods comprise detecting whether the envelope protein from an HIV from the patient comprises a mutation or mutations in codons 117, 421, 121, and/or 298, wherein the presence of the mutation or mutations indicates that the HIV is likely to be more susceptible to the entry inhibitor than the reference HIV.